Английская Википедия:Fluorodopa
Шаблон:Short description Шаблон:Distinguish Шаблон:Use dmy dates Шаблон:Drugbox
Fluorodopa, also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).[1]
The most common side effects are injection site pain.[2]
Medical uses
Fluorodopa is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes (PS).[2]
History
In October 2019, Fluorodopa was approved in the United States for the visual detection of certain nerve cells in adult patients with suspected Parkinsonian Syndromes (PS).[3][4]
The U.S. Food and Drug Administration (FDA) approved Fluorodopa F 18 based on evidence from one clinical trial of 56 patients with suspected PS.[3] The trial was conducted at one clinical site in the United States.[3]
References
External links
Шаблон:Diagnostic radiopharmaceuticals Шаблон:Portal bar
